As the use of immunotherapies expands, understanding and managing their associated arrhythmic complications is crucial for cardio-oncology care.
Purpose of Review Immunotherapies have revolutionized treatment strategies for cancer patients, improving the prognosis in many populations with advanced malignancies. Immune check point inhibitors (ICI) and Chimeric antigen receptor (CAR) T cell therapy are being increasingly used. As the real-world use of immunotherapies increases and indications expand, an understanding of potential cardiovascular toxicities is required. Recent Findings Arrhythmias are among the top reasons for seeking cardiovascular care in immunotherapy treated patients. ICI and CART therapies have been associated with arrhythmias with wide range of estimates reported in randomized clinical trials and retrospective studies. The pathophysiology and risk factors behind ICI and CART therapies is unclear. Summary In this review, we summarize the incidence, mechanisms, risk factors, impact on patient outcomes and management of ICI and CAR-T cell therapy-associated arrhythmia complications.
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2026) conducted a review in Cancer (Immunotherapy-related cardiac arrhythmias). Immunotherapy (Immune Checkpoint Inhibitors and CAR-T cell therapy) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: